↑ 薬物リストへ　← 戻る

Epa and dha    (DrugBank: -)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
113筋ジストロフィー1

113. 筋ジストロフィー　［臨床試験数：567，薬物数：442（DrugBank：93），標的遺伝子数：55，標的パスウェイ数：151］
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 567 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01826422
(ClinicalTrials.gov)		March 20134/4/2013Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB PatientsEffect of Eicosapentaenoic Fatty Acid (EPA) and Docosahexaenoic Fatty Acids (DHA) Supplementation on the Inflammation State and Metabolic Disorders in Patients With Duchenne Muscular Dystrophy or Becker Muscular DystrophyMuscular Dystrophy, DuchenneDietary Supplement: EPA and DHA;Dietary Supplement: Placebo ComparatorCoordinación de Investigación en Salud, MexicoInstituto Nacional de RehabilitacionCompleted6 Years18 YearsMale40N/AMexico